AssetMark Inc’s 4D Molecular Therapeutics FDMT Stock Holding History

AssetMark Inc’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$329	Buy	+23	New	+$299	﹤0.01%	3526

Other funds holding FDMT

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Perigon Wealth Management San Francisco, California $6.5B AUM 20.72% 1-Year Est. Return

Hussman Strategic Advisors Ellicott City, Maryland $469M AUM 10.16% 1-Year Est. Return

Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

AssetMark Inc's FDMT Position: Q3 2026 in Review

AssetMark Inc opened a new position in 4D Molecular Therapeutics (FDMT) in Q3 2026: 23 shares worth $329. The stake represents ﹤0.01% of the portfolio and ranks #3526 among its holdings.

40 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.

AssetMark Inc held 23 shares of 4D Molecular Therapeutics worth $329 as of Q3 2026.
4D Molecular Therapeutics was a new AssetMark Inc position in Q3 2026.
4D Molecular Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #3526 holding.
40 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.